Jak inhibitors: Beyond spleen and symptoms?

Haematologica

Volumn 98, Issue 2, 2013, Pages 160-162

  Cervantes, Francisco ^a   Mesa, Ruben ^b   Harrison, Claire ^c  

^a UNIVERSITY OF BARCELONA   (Spain)

^b MAYO CLINIC   (United States)

^c GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE INHIBITOR; MOMELOTINIB; N TERT BUTYL 3 [5 METHYL 2 [4 [2 (1 PYRROLIDINYL) ETHOXY] PHENYLAMINO] 4 PYRIMIDINYLAMINO] BENZENESULFONAMIDE; N TERT BUTYL 3 [5 METHYL 2 [4 [2 (1 PYRROLIDINYL)ETHOXY]PHENYLAMINO] 4 PYRIMIDINYLAMINO]BENZENESULFONAMIDE; PLACEBO; RUXOLITINIB; UNCLASSIFIED DRUG; JANUS KINASE; PROTEIN KINASE INHIBITOR;

ANEMIA; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EDITORIAL; ERYTHROCYTE TRANSFUSION; FOLLOW UP; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; INCIDENCE; MYELOPROLIFERATIVE NEOPLASM; NAUSEA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SPLEEN; THROMBOCYTOPENIA; ANTAGONISTS AND INHIBITORS; PRIMARY MYELOFIBROSIS; TREATMENT OUTCOME;

CLINICAL TRIALS, PHASE II AS TOPIC; HUMANS; JANUS KINASES; PRIMARY MYELOFIBROSIS; PROTEIN KINASE INHIBITORS; TREATMENT OUTCOME;

EID: 84875309299     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2012.083543     Document Type: Editorial

References (12)

1. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799-807.
2. Harrison C, Kiladjian J-J, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, et al. JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis. N Engl J Med. 2012;366(9):787-98.
3. Verstovsek S, Kantarjian HM, Estrov Z, Cortes JE, Thomas DA, Kadia T, et al. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood. 2012;120(6):1202-9.
4. Tefferi A, Litzow MR, Pardanani A. Long-term outcome of treatment with ruxolitinib in myelofibrosis. N Engl J Med. 2011;365(15):1455-7.
5. Cervantes F, Kiladjian J-J, Niederwieser D, Sirulnik A, Stalbovskaya V, McQuity M, et al. Long-Term Safety, Efficacy, and Survival Findings From Comfort-II, a Phase 3 Study Comparing Ruxolitinib with Best Available Therapy (BAT) for the Treatment of Myelofibrosis (MF). ASH Annual Meeting Abstracts. 2012;120(21):801.
6. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al. Long-Term Outcome of Ruxolitinib Treatment in Patients with Myelofibrosis: Durable Reductions in Spleen Volume, Improvements in Quality of Life, and Overall Survival Advantage in COMFORT-I. ASH Annual Meeting Abstracts. 2012;120(21):800.
7. Talpaz M, Jamieson C, Gabrail NY, Lebedinsky C, Gao G, Liu F, et al. A Phase II Randomized Dose-Ranging Study of the JAK2-Selective Inhibitor SAR302503 in Patients with Intermediate-2 or High-Risk Primary Myelofibrosis (MF), Post-Polycythemia Vera (PV) MF, or Post- Essential Thrombocythemia (ET) MF. ASH Annual Meeting Abstracts. 2012;120(21):2837.
8. Pardanani A, Gotlib J, Gupta V, Roberts AW, Wadleigh M, Sirhan S, et al. Phase I/II Study of CYT387, a JAK1/JAK2 Inhibitor for the Treatment of Myelofibrosis. ASH Annual Meeting Abstracts. 2012;120(21):178.
9. Baerlocher GM, Leibundgut EO, Ayran C, Blaney M, Burington B, Morfeld D, et al. Imetelstat Rapidly Induces and Maintains Substantial Hematologic and Molecular Responses in Patients with Essential Thrombocythemia (ET) Who Are Refractory or Intolerant to Prior Therapy: Preliminary Phase II Results. ASH Annual Meeting Abstracts. 2012;120(21):179.
10. Vannucchi AM, Passamonti F, Al-Ali HK, Barosi G, Harrison CN, Sirulnik A, et al. Reductions in JAK2 V617F Allele Burden with Ruxolitinib Treatment in Comfort-II, a Phase 3 Study Comparing the Safety and Efficacy of Ruxolitinib with Best Available Therapy (BAT). ASH Annual Meeting Abstracts. 2012;120(21):802.
11. Pardanani A, Gotlib JR, Jamieson C, Cortes JE, Talpaz M, Stone RM, et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol. 2011;29(7):789-96.
12. Geyer HL, Dueck AC, Emanuel RM, Kiladjian J-J, Slot S, Zweegman S, et al. The Myelofibrosis Symptom Burden (MF-SB): An International Phenotypic Cluster Analysis of 329 Patients. ASH Annual Meeting Abstracts. 2012;120(21):1731.